Prosecution Insights
Last updated: October 04, 2026

Scf Pharma Inc.

Technology area: Biotechnology & Pharmaceuticals

1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready

Analysis

Scf Pharma Inc. currently has 1 pending office action within the Biotechnology & Pharmaceuticals technology area. This matter is assigned to 1 distinct examiner, ROCHELLE, CIERRA MARIE, and is located in 1 distinct art unit. ROCHELLE, CIERRA MARIE is the busiest examiner with 1 busiest examiner pending action, representing the entire current workload for this portfolio.

The presence of 1 pending office action indicates a focused prosecution effort. Because the portfolio involves only 1 distinct examiner and 1 distinct art unit, the strategy is entirely dependent on the specific tendencies of a single individual. There are no other pending matters in the data to provide a baseline for comparison within the company's own history. Practitioners should focus on the historical patterns of ROCHELLE, CIERRA MARIE and the specific standards of the 1 art unit involved. This consolidation simplifies the administrative tracking of the portfolio but also means that progress is tied to a single point of review for the 1 pending office action.

Written from this page's own data; every figure is computed from USPTO records and verified before publication.

Portfolio Summary

1
Total Pending OAs
1
Non-Final OAs
0
Final Rejections
0
Advisory / Quayle

Case Difficulty Mix

Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.

0
Hard (0%)
1
Medium (100%)
0
Easy (0%)
0
Unknown (0%)

Rejection Statute Mix

BucketCases
Double-patenting + other1 (100%)

Industry Mix

How the docket's pending cases split across USPTO tech-center bands.

1
Life Sciences
100% of docket
0
Information Tech
0% of docket
0
Communications
0% of docket
0
Semiconductors
0% of docket
0
Mechanical / Eng
0% of docket
0
Business / Other
0% of docket

Time-on-OA Estimate

Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.

10 h
Manual time on pending OAs
2 h
Time saved (low, 20%)
4 h
Time saved (mid, 35%)
0.1 wks
FTE-weeks freed (mid)

Top Examiners on this docket

ExaminerApps on this docketAllow rateInterview lift
ROCHELLE, CIERRA MARIE 1 100.0% +0.0%

Quick Wins (1)

Cases in front of an examiner with an allow rate of 80%+ where the difficulty is Easy or Medium. The top 1 ordered by deadline are shown.

App #TitleExaminerDue in
18725239 POLYUNSATURATED FATTY ACID MONOGLYCERIDES, COMPOSITIONS, METHODS AND USES THEREOF ROCHELLE, CIERRA MARIE —

Top Art Units

Art UnitApps
1627 1

Pending Office Actions

App #TitleExaminerArt UnitStatutesStatusDue inAIFiled
18725239 POLYUNSATURATED FATTY ACID MONOGLYCERIDES, COMPOSITIONS, METHODS AND USES THEREOF ROCHELLE, CIERRA MARIE 1627 §103§112DP Non-Final OA — Pending Jun 28, 2024

Managing Scf Pharma Inc.'s Patent Portfolio?

IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.

Start Free Trial

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month